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Protocol
AbstrACt
Objective Depressive symptoms are common among 
people with dementia, impacting quality of life and 
cognitive and functional decline. Currently, little is known 
about the acceptability and feasibility of psychological 
interventions for people with mild dementia, with recent 
reviews identifying the need for further evidence. 
Developing and evaluating psychological interventions 
to prevent and treat these symptoms is, therefore, an 
important clinical and research priority. This protocol 
describes a study testing the acceptability and feasibility 
of a manual-based behavioural activation (BA) intervention 
for preventing and treating depressive symptoms in people 
with mild dementia. The aim of this study is to explore 
the feasibility of conducting a pragmatic multicentre 
randomised controlled trial of clinical effectiveness of an 
eight-session intervention. The Intervention to prevent 
Depressive symptoms and promote well-being in EArly-
stage dementia (IDEA) programme supports people 
with dementia and their family carers in identifying and 
scheduling enjoyable and meaningful activities.
Methods and analysis Sixty people who have received 
a diagnosis of dementia of any type in the last 6 months 
will be recruited via memory clinics. Further criteria are a 
Mini-Mental State Examination score of ≥20, and a family 
carer who can assist with the intervention. Consenting 
participants will be randomised in a ratio of 2:1 to BA or 
to treatment as usual. Analyses will estimate parameters 
such as rates of recruitment, retention and number 
of sessions completed. Questionnaires measuring 
depressive symptoms and quality of life for both the 
person with dementia and their carer will be completed 
at baseline, 3 and 6 months. Qualitative interviews 
will explore acceptability of the intervention, study 
procedures and experiences of the sessions.
Ethics and dissemination This study received a 
favourable ethical opinion from the London Camberwell 
St Giles Research Ethics Committee (16/LO/0540). We will 
disseminate findings at key conferences, the Alzheimer’s 
Society and University College London websites and local 
stakeholder events.
trial registration number ISRCTN75503960; Pre-results.
IntrOduCtIOn  
Dementia is a leading cause of disability in late 
life,1 with economic costs to society expected to 
double from £26 billion per year to £55 billion 
in 2040 in the UK alone.2 There are currently 
over 50 million people living with dementia, 
with numbers of people affected expected to 
increase to 66 million by 2030.3 4 People with 
dementia are at increased risk of experiencing 
psychological distress such as depression,5 6 
which is not only distressing but persistent and 
associated with increasing cognitive and func-
tional decline,7 8 a risk of earlier care-home 
admission9 and reduced life expectancy.10 In line 
with current National Health Service policies 
and the National Dementia Strategy,11 accessing 
emotional, social and practical support after 
diagnosis is an important and timely objective 
for people with dementia,12 13 and it is reason-
able to assume that people with dementia who 
additionally experience symptoms of depres-
sion will require more resources and support. 
In a review of experiences of postdiagnostic 
treatment, psychological care for people with 
dementia was described as least developed,14 
indicating that access to psychological support 
strengths and limitations of this study
 ► This will be the first study to provide acceptability 
and feasibility data for a psychological intervention 
based on behavioural activation for preventing and 
treating depressive symptoms in people with mild 
dementia.
 ► Explores feasibility parameters such as rates of 
recruitment, follow-up retention and number of 
sessions completed, with several proposed outcome 
measures tested for suitability of a full-scale trial.
 ► By using both quantitative and qualitative data, the 
results will inform a future large-scale randomised 
controlled trial of clinical effectiveness.
 ► Limited to follow-ups at 3 and 6 months.
 ► People with dementia and their carers will be 
recruited from two London National Health Service 
sites which may be associated with sample 
selection bias.
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remains poor despite an increasing emphasis on supporting 
people to maintain a sense of well-being.
Current estimates show that up to 50% of people 
living with dementia experience depression at least once 
during the course of the disease.15 Major depressive 
disorder affects approximately 20%–30% of people with 
dementia,7 15 with personal or family history of depres-
sion16 and a younger age at onset of dementia increasing 
the risk of depression.17Subclinical or subthreshold symp-
toms of depression occur at a higher rate than clinical 
depression,18 tend to be highly persistent7 and are often 
experienced during the early stages of the disease.19 
Both depression and less severe depressive symptoms 
are sources of excess disability for people with dementia, 
therefore both major and subthreshold symptoms of 
depression are considered clinically important.18 20
Although depression is associated with high burden 
for people with dementia and their carers, there are 
currently no interventions available to prevent depres-
sive symptoms occurring or becoming worse, which is key 
given poor efficacy of antidepressants.21 Despite limited 
efficacy of pharmacological interventions and increased 
risk of side effects, about a third of people with Alzhei-
mer’s disease living in the community are prescribed anti-
depressants,22 23 and up to 40% in care homes24 indicating 
a high need to manage these symptoms.19
A Cochrane Review25 of the effects of psychological treat-
ments for people with dementia found that these treatments 
may contribute to a reduction in depressive symptoms, 
however evidence comes mostly from small-scale studies, 
with heterogeneous treatments.25 A recent systematic review 
of behavioural activation (BA) interventions for older people 
found that these are associated with a reduction in depres-
sive symptoms in older people without dementia living in the 
community.26 The review also highlighted that most studies 
so far including people with dementia do not use well-de-
fined interventions. The long-term aim of this research is to 
test the effectiveness and cost-effectiveness of BA for people 
with dementia living in the community.
This study aims to establish the acceptability and feasi-
bility of an 8-week intervention using BA principles27 28 
developed after extensive consultations and field testing 
with people with mild dementia and their family carers. 
The study design is a feasibility randomised controlled 
trial (RCT), with two treatment arms (BA vs treat-
ment as usual) following participants over 8 months. A 
secondary objective is to test the feasibility of procedures 
for conducting and planning a multicentre RCT by 
exploring trial processes, and acceptability and feasibility 
of the intervention.
MEthOds And AnAlysIs
Participant recruitment
Inclusion criteria
Participants will be people who have received a diagnosis 
of dementia of any type in the last 6 months and: (1) are 
living in the community, (2) have a family carer who is 
available to participate and support the person in the 
intervention and (3) have mild dementia (determined by 
a Mini- Mental State Examination score of ≥20).
Exclusion criteria
Participants will be excluded if (1) they are deemed by 
their clinical team to be at risk of self-harm (excluding 
neglect) or a risk to others, (2) have difficulties commu-
nicating in English or (3) are already taking part in 
another intervention study. People with previous depres-
sion, or previous or current treatment with antidepres-
sants or experience of psychological treatments will not 
be excluded. The study will recruit a total of 60 people 
with dementia and their carers from memory clinics 
and community mental health teams of older people 
in London. Potential participants will be recruited by 
clinicians in relevant Trusts, by invitation letter or by a 
‘consent to contact’ approach.
sample size considerations and randomisation
A total of 60 people will be recruited29 30 and randomised 
in a ratio of 2:1 to either the BA intervention or treatment 
as usual. Among the 40 participants in the BA arm, we will 
be able to estimate 75% acceptability of the IDEA inter-
vention with a 95% CI of 59% to 87%.
Participant randomisation will be undertaken at 
University College London (UCL) using a randomisa-
tion system stratified by site provided by internet-based 
sealed envelope codes, based on random permuted 
blocks of sizes three and six to allow a 2:1 allocation to 
intervention and treatment as usual. Randomisation allo-
cation will be sent by automated email, to the non-blind 
researcher performing the randomisation using their 
unique user name and password.
treatment as usual
This study is designed to be a pragmatic feasibility study, 
and no participants will be denied access to any treat-
ment that they would have had access to. Both groups will 
receive regular treatment as usual, which is expected to 
be in line with the National Institute for Health and Care 
Excellence guidelines for treatment of dementia, details 
of which will be recorded for each participant using the 
Client Service Receipt Inventory (CSRI).31
blinding
All follow-up assessments will be conducted by a researcher 
who is blind to treatment allocation. In trials of psycho-
logical interventions, it is difficult to blind therapists and 
participants to which intervention they are delivering or 
receiving. Any incidents of non-blinding will be recorded 
to inform the future trial.
Intervention
The proposed intervention will follow theory and models 
of BA,27 28 and key components identified to be associ-
ated with effectiveness in trials of older people.26 BA is 
defined as a brief structured therapeutic approach aimed 
at increasing engagement in adaptive activities often 
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associated with pleasure and mastery, through structured 
activity scheduling and monitoring of mood, supple-
mented by additional behavioural strategies, such as 
relaxation techniques, and hierarchical construction of 
goals.26
The IDEA intervention will include:
a. identifying pleasant activities for the person and de-
veloping and agreeing a plan of which activities to 
implement
b. setting goals about implementing these activities
c. monitoring and reviewing activities on a weekly basis
d. teaching of specific relaxation skills32
e. discussing accessing help
f. making a plan for the future.
The intervention will be an individual home-based 
manualised programme, comprised of a total of eight 
weekly 1-hour sessions, delivered by a psychology grad-
uate who will be trained in the intervention and super-
vised monthly by one of the coinvestigators. Based on 
the suggestions and observations when developing the 
intervention, session frequency will depend on partici-
pants, with sessions completed over 8–12 weeks.
Adherence to treatment protocol
A manual guiding therapists in delivering the interven-
tion will be developed, describing its key components. 
The feasibility of the treatment-adherence measures and 
competency assessment will be assessed by developing a 
checklist for use in the main trial.
subsequent assessments of outcomes
All participants receiving the intervention will be asked to 
complete a follow-up qualitative interview at their home 
administered by a researcher not providing the inter-
vention. These interviews will examine experiences and 
expectations of the intervention, and suitability of inter-
vention materials in order to inform their further refine-
ment in the main trial. Participants will be recruited until 
theoretical saturation has been achieved. Data on accept-
ability, completion rates and attrition will be supple-
mented by qualitative data.
Proposed outcome measures for the full-scale clinical trial
The flow diagram of the current trial is presented in 
figure 1. In order to inform the future trial, outcome 
measures will be trialled for suitability. Depressive symp-
toms is proposed as the outcome for the main study. 
Carers will complete generic health and quality of life 
measures, and resource use questionnaires to examine 
the feasibility of cost-effectiveness analysis. Question-
naires will be completed at baseline, 3 and 6 months after 
randomisation.
Outcomes tested for acceptability for the main trial
1. Depressive symptoms—Cornell Scale for Depression 
in Dementia (CSDD).33 The CSDD is a 19-item inter-
viewer-administered measure which uses information 
provided by interviewing the person with dementia 
and their carer. Symptoms are described to the carer 
as they appear on the scale. Where there is a discrep-
ancy between the carer and the researcher’s ratings 
the carer is reinterviewed before making a final 
judgement.
2. Self-rated and carer-rated dementia-specific quality 
of life for the person with dementia—DEMQOL and-
DEMQOL-proxy.34 The DEMQOL measures quality of 
life,35 in five domains, including daily activities, health 
and well-being, cognitive functioning, social relation-
ships and self-concept. The scale is used as a self-rated 
or carer-rated report, administered to the person with 
dementia and carer, with established validity.36
3. Self-rated and carer-rated quality of life using the Eu-
ropean Quality of Life-5 Dimensions (EQ-5D) for the 
person with dementia, measured using the three-level 
response version of the EQ-5D, a standardised instru-
ment for use as a measure of health outcome.37
4. Neuropsychiatric symptoms—Neuropsychiatric In-
ventory (NPI).38 The NPI assesses 12 behavioural dis-
turbances occurring in people with dementia as rated 
by the carer, using a screening strategy to minimise 
administration time by examining and scoring only 
those behavioural domains that have positive respons-
es to screening questions. Both frequency and severity 
of each behaviour are also rated with higher scores 
indicative of more symptoms. Both validity and reli-
ability of the measure have been established.35
5. Health services utilisation—CSRI.39 The CSRI will be 
used to collect feasibility data on the use of health and 
social care services provided by public or non-public 
bodies, and information on carers’ costs and partici-
pants’ use of health and social care services to inform 
the full trial. The feasibility of collecting service-use 
data will be assessed, which will allow identification of 
services received in both groups and any changes that 
may occur.
6. Carers’ mental health—Hospital and Anxiety De-
pression Scale (HADS).40 Depressive and anxiety 
symptoms in carers will be measured using HADS, a 
self-rated measure, generating scores for both gener-
alised anxiety and depressive symptoms, used widely 
to identify caseness for clinically significant depres-
sion and anxiety.41
7. Carers' quality of life—the EQ-5D37 and Short Form-
12 Health Survey (SF-12).42 Carer health-related qual-
ity of life will be measured using the EQ-5D. Carers’ 
mental and physical health will be measured by the 
SF-12, measuring health by standardised responses, 
expressed in terms of two meta-scores: the physical 
component summary and the mental component 
summary.
safety monitoring
Adverse events will be closely monitored. These are events 
that are likely to affect to a significant degree the safety 
or physical or mental integrity of the participants in the 
trial. The sponsor will be notified immediately of any case 
where the above definition applies during the trial.
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statistical analysis plan
Given this is a feasibility study, it does not aim to provide a 
hypothesis test of the effectiveness of the intervention but 
to estimate feasibility study parameters. The main aims, 
therefore, are feasibility of the randomised controlled 
study and acceptability of the intervention for people 
with dementia and their carers. We will, therefore, test 
analysis procedures in order to inform the statistical anal-
ysis plan of the main trial as opposed to making statistical 
comparisons of outcomes between the intervention and 
treatment as usual groups. The analyses will include the 
following:
 ► rates of clinicians’ referrals, number of participants 
recruited and randomised to the study (number of 
Figure 1 Flow diagram. NHS, National Health Service.
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dyads referred and recruited per month, percentage 
reaching inclusion criteria and any barriers or facilita-
tors to recruitment);
 ► percentage of eligible participants who consent to the 
study;
 ► percentage of BA sessions completed (percentage in 
the BA group completing all sessions);
 ► follow-up rates and number completing each outcome 
measure proposed for the main trial.
We will produce a Consolidated Standards of 
Reporting Trials diagram to represent numbers of 
people with dementia eligible for inclusion, numbers 
recruited, randomised and completing the study. Details 
of participants who meet the inclusion criteria but are 
not randomised will be recorded in order to inform 
the future trial. Essential baseline information will be 
recorded which will include quantitative and qualita-
tive information (ie, specifics of diagnosis, psychiatric 
history, use of medications and demographics). In line 
with the current recommendations of Good Clinical 
Practice, analyses will be descriptive. We will estimate SDs 
(95% CIs) of potential outcome measures at baseline, 3 
and 6 months and changes in scores from baseline. We 
will use rates of missing questionnaire data to inform the 
full trial. For the feasibility economic evaluation compo-
nent, we will collect data on resource use and costs for 
the future trial including resources required to deliver 
the intervention.
EthICs And dIssEMInAtIOn
Ethics
The study is registered as a clinical trial and has been allo-
cated an International Standard Randomised Controlled 
Trial Number (ISRCTN75503960). As the intervention 
is a psychological therapy, the trial is not covered by the 
Medicines for Human Use (Clinical Trials) Regulations 
2004.
Informed consent and withdrawal from the study
Participants will be in the mild stages of dementia, and 
therefore would generally be expected to be able to 
provide informed consent. In instances where the partic-
ipant’s level of impairment increases, such that they are 
no longer able to provide informed consent, the provi-
sions of the Mental Capacity Act will be followed. Partic-
ipants will be informed of their right to withdraw at any 
time without their care being affected in any way.
data management
All participant information will be stored in accordance 
with the UK Data protection Act 1998 guidance, with all 
personally identifiable information stored in locked cabi-
nets and stored separately from study data which will be 
anonymised and saved on password-protected computers 
at UCL, in line with UCL Data Protection Policy.
Patient and public involvement
Local user groups of people with dementia and their 
carers, and professionals supporting them have been 
consulted and involved in the design of the study, the 
development of the intervention and recruitment strat-
egies.43 A dissemination strategy will be developed that 
will identify key stakeholder groups who will be commu-
nicated of the study’s findings. We will also consult our 
Patient and Public Involvement members for the design 
of the main trial.
Oversight committees
A Trial Steering Committee has been set-up and will 
include an independent chair, two independent members 
and the study’s coinvestigator(s).
dIsCussIOn
This study will evaluate the acceptability and feasibility 
of a psychological intervention using BA principles to 
prevent and treat depressive symptoms for people with 
mild dementia informing a clinical and cost-effective-
ness trial. In line with Medical Research Council guide-
lines,44 we will use data from this study to further refine 
the intervention, produce a training package  and inform 
approaches for recruitment and analyses for the full-scale 
trial. This feasibility study is necessary preparatory work 
to inform a full RCT and the psychological care of people 
with dementia.
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